Testosterone: keep the treatment goal specific

Testosterone is sometimes considered for persistent, distressing low sexual desire around menopause. It is not a routine requirement for every woman, and a low laboratory result alone does not establish a need for treatment. The best-supported use is a carefully assessed sexual-health concern, not general promises about energy, weight loss, memory or reversing ageing. [1]

This guide separates the treatment discussion from marketing language. Prescribing, product licensing and access vary between countries, so decisions should be made with a qualified clinician using current local information.

Start with the concern, not the hormone result

Sexual desire varies between people and over time. Having less interest in sex than a partner, or less interest than earlier in life, is not automatically a disorder. What matters is whether the change is distressing to you and whether you would like support. There is no required frequency of sex that defines good health. [2]

A clinician may discuss hypoactive sexual desire disorder, often shortened to HSDD. Assessment considers the nature of the concern, the distress involved and other possible explanations. A blood test cannot replace that discussion or decide whether a relationship is satisfying.

Describe what you miss: interest, arousal, enjoyment, comfort, emotional closeness or confidence. These are related but not identical. Treating painful penetration, for example, is a different task from addressing desire when sex is comfortable but no longer appealing.

What does the evidence support?

The international consensus statement identifies postmenopausal women with HSDD following a biopsychosocial assessment as the evidence-based group for testosterone treatment. Biopsychosocial means considering physical health, psychological wellbeing and the relationship or social context together. It does not imply that symptoms are imaginary. [1]

Research supporting this indication should not be stretched into a guarantee that testosterone treats all menopause symptoms. Claims about preventing dementia, building muscle, restoring motivation or improving general wellbeing require their own evidence. A biological role for a hormone does not prove that adding more improves each related function.

Ask a clinician to distinguish established uses, uncertain possibilities and treatments offered outside the strongest evidence. You are entitled to understand those boundaries before paying for testing or committing to a long prescription plan. A confident sales presentation is not the same as a well-supported explanation.

What should be assessed first?

Pain, vaginal dryness, medication effects, relationship difficulties, depression, anxiety, fatigue and disturbed sleep may affect sexual experience. Assessment should explore the factors relevant to you, without assuming that one problem explains them all. Some can be addressed alongside a testosterone discussion rather than used to dismiss it. [2]

Mention antidepressants and other prescribed medicines, but do not stop them yourself to test whether desire changes. Explain any previous sexual difficulties, cancer treatment, pelvic surgery or major change in health. A clinician may ask sensitive questions; you can ask why they are relevant and decline to answer at that moment.

A partner can attend by invitation, but there should also be an opportunity to speak privately. The goal is your wellbeing and autonomy, not meeting someone else’s expectations. No treatment should be presented as an obligation to become more sexually available.

How does testosterone fit with HRT and local care?

UK menopause guidance considers testosterone for low sexual desire associated with menopause when HRT alone has not been effective. The sequence and suitability depend on the individual history. Treatment for vaginal discomfort may also be needed; improving desire does not automatically make painful sex comfortable. [3]

Systemic oestrogen, progesterone where required, local vaginal treatment and testosterone have different roles. Request a clear account of what each proposed medicine is intended to improve. More products do not necessarily mean more comprehensive care, and one hormone should not be used as a substitute for another’s safety function.

A coordinated plan can also include psychosexual therapy, relationship support or changes to a medicine that is contributing to difficulties. Read relationships and intimacy and vaginal oestrogen for related discussions that may be relevant before or during treatment.

What can blood tests tell you?

Testosterone testing can help establish a baseline and monitor against excessive exposure during treatment. It is not a simple diagnostic test for low desire. Results need interpretation alongside symptoms, the laboratory method and the treatment being used; an isolated number should not become a target to maximise. [1]

Ask what will be measured, when it will be repeated and who will act on the result. The correct timing may depend on the preparation and how it is used. Tell the clinician and laboratory about all hormone products, including creams from another clinic or products bought online.

Do not change the prescribed amount to reach the top of a reference range. More is not automatically better, and a result within a laboratory interval is not the only measure of safety or benefit. Clinical response and adverse effects need attention as well.

Product status and availability need checking

Product licensing can change, so check current regulatory information rather than relying on an old article or a clinic’s general statement about availability. In the UK, the MHRA product database is a starting point for checking the exact preparation. Regulatory information alone does not establish current pharmacy stock, NHS funding or suitability for an individual patient. Ask the prescriber and dispensing pharmacist to confirm those separate questions. [4]

Ask whether the exact proposed product is licensed for your indication in your country. Where prescribing is off-label or an unlicensed preparation is considered, request an explanation of the reason, evidence, alternatives and monitoring responsibilities. Those terms should be explained rather than hidden or used to frighten you.

Do not purchase testosterone from a seller who bypasses proper assessment. Different strengths and delivery systems are not interchangeable. A product intended for another population can create dosing difficulties that require a prescriber’s precise instructions, not an online conversion or a friend’s routine.

What risks and uncertainties should be discussed?

Unwanted effects can include acne and increased hair growth. Excess exposure can cause more concerning androgenic changes, including scalp hair loss or voice changes. Long-term safety evidence has limitations, particularly when treatment is extended beyond the populations and durations studied. Ask how these uncertainties apply to your circumstances. [1]

Discuss pregnancy possibility, breastfeeding, liver disease, a history of hormone-sensitive cancer and any previous adverse reaction before treatment. A prescriber may need specialist advice or may recommend another approach. Testosterone is not contraception and should not be treated as a way to establish that pregnancy can no longer occur.

With skin-applied products, follow the specific instructions to reduce unintended transfer to other people. Ask about application, handwashing, covering the area and contact with children or partners. Do not assume that instructions for one cream or gel apply to another formulation.

Agree what success would mean

The outcome should be meaningful to you: less distress about desire, more interest in intimacy or improved sexual wellbeing. A higher blood result, a change in an app score or a clinician’s satisfaction is not enough on its own. Keep expectations realistic rather than treating treatment as a test of whether your relationship can succeed.

Ask when benefit will be assessed and what would lead to stopping or reconsidering treatment. A trial should have a purpose and a review, not become indefinite simply because prescriptions are easy to renew. Bring both positive changes and unwanted effects to that review.

When benefit is unclear, review the wider picture instead of automatically increasing the amount. Has pain remained untreated? Is sleep still severely disrupted? Has another medicine changed? The answer may be a revised plan, a different form of support or deciding the trial has not been worthwhile.

Recognising unsupported sales claims

Be cautious when a clinic diagnoses universal testosterone deficiency from a symptom quiz, promises broad rejuvenation or recommends the same combination for every client. Testimonials describe individual experiences, not the chance of benefit or risk for a new patient. They cannot resolve uncertainty about long-term safety.

Ask for the clinical indication in ordinary language and the evidence specific to that indication. Request the complete cost of consultations, tests, prescriptions and follow-up. A package should not require accepting an unwanted treatment in order to receive help for a separate menopause symptom.

Compounded mixtures and implanted preparations warrant questions about regulation, dose consistency, adjustment and what happens if adverse effects occur. Our bioidentical hormones guide explains why the words natural and personalised are not substitutes for product-specific evidence or quality controls.

A useful appointment checklist

Bring a medication list, your main concern, relevant medical history and any previous results. Note whether the change is distressing to you, whether pain is involved and which outcomes matter. You do not need to arrive with a diagnosis or prove that you have tried every possible lifestyle change.

Before agreeing, understand the product, indication, monitoring plan, likely costs and contact route for side effects. Ask how the prescriber will coordinate with other clinicians and what happens if you move or no longer use the clinic. Continuity matters when a treatment depends on specialist oversight.

Most importantly, the decision remains yours. You may choose a trial, another approach or no medicine. A good consultation should leave you better informed about sexual wellbeing, not convinced that a single hormone determines your femininity, attractiveness or value.